' 
![]()
SCIENTIFIC SCORE
Possibly Effective
Based on 26 Researches
7.5
USERS' SCORE
Good
Based on 5 Reviews
8.7
Supplement Facts
Serving Size: 2 Softgels
Amount Per Serving
%DV
Calories
20
Total Fat
2 g
3%**
Saturated Fat
0.5 g
3%**
Polyunsaturated Fat
1 g
†
Monounsaturated Fat
0.5 g
†
Fish Oil Concentrate
2 g (2,000 mg)
†
Eicosapentaenoic Acid (EPA)
360 mg
†
Docosahexaenoic Acid (DHA)
240 mg
†
Top Medical Research Studies
9
DHA enhances sickle cell outcomes
SC411 treatment can enhance survival in a mouse model of sickle cell disease.
Study shows mixed fatty acid effects
We explored the potential of docosahexaenoic acid (DHA) as a treatment for anemia in sickle cell disease (SCD). In this study, we utilized a special mouse model that mimics SCD, testing how SC411—a purified form of DHA—affects this condition.
After eight weeks of treatment, we observed that DHA levels, along with eicosapentaenoic acid (EPA), significantly increased in the blood of the SCD mice. Alongside these positive changes, we found that SC411 also reduced levels of arachidonic acid, minimizing the sickling of red blood cells, which is a major issue in SCD.
Notably, mice that received SC411 showcased improvements in blood flow to the brain, a decrease in neuroinflammation, and even an enhancement in working memory. These findings ultimately led to improved survival rates among the treated mice, suggesting that DHA can offer a promising therapeutic avenue for individuals suffering from SCD and its related anemia.
After eight weeks of treatment, we observed that DHA levels, along with eicosapentaenoic acid (EPA), significantly increased in the blood of the SCD mice. Alongside these positive changes, we found that SC411 also reduced levels of arachidonic acid, minimizing the sickling of red blood cells, which is a major issue in SCD.
Notably, mice that received SC411 showcased improvements in blood flow to the brain, a decrease in neuroinflammation, and even an enhancement in working memory. These findings ultimately led to improved survival rates among the treated mice, suggesting that DHA can offer a promising therapeutic avenue for individuals suffering from SCD and its related anemia.
Read More
9
Maresin 1 helps treat anemia
Maresin 1 ameliorates iron-deficient anemia in IL-10(-/-) mice with spontaneous colitis by the inhibition of hepcidin expression though the IL-6/STAT3 pathway.
Study directly investigates MaR1 effects
We focused on how Maresin 1, a compound derived from docosahexaenoic acid, might help improve iron-deficient anemia in mice with chronic colitis. Our research involved IL-10 knockout mice, which are known to develop spontaneous colitis and associated anemia.
Over two weeks, we treated these mice with MaR1, observing several important changes. We found that MaR1 significantly reduced inflammation in the colon and was associated with a boost in hemoglobin levels, increased serum iron, and improved transferrin saturation.
Additionally, we noted that the levels of hepcidin, a protein that regulates iron metabolism and is often elevated during inflammation, decreased after treatment. This suggests that MaR1 helps combat anemia by influencing this protein's expression through the IL-6/STAT3 pathway.
Overall, we uncovered promising evidence that MaR1 has the potential to alleviate anemia connected to inflammatory processes, making it a noteworthy area for further exploration in treating patients with similar conditions.
Over two weeks, we treated these mice with MaR1, observing several important changes. We found that MaR1 significantly reduced inflammation in the colon and was associated with a boost in hemoglobin levels, increased serum iron, and improved transferrin saturation.
Additionally, we noted that the levels of hepcidin, a protein that regulates iron metabolism and is often elevated during inflammation, decreased after treatment. This suggests that MaR1 helps combat anemia by influencing this protein's expression through the IL-6/STAT3 pathway.
Overall, we uncovered promising evidence that MaR1 has the potential to alleviate anemia connected to inflammatory processes, making it a noteworthy area for further exploration in treating patients with similar conditions.
Read More
8
SC411 boosts survival in SCD
SC411 treatment can enhance survival in a mouse model of sickle cell disease.
Focus on eicosapentaenoic acid
We explored how a treatment called SC411, which is enriched with eicosapentaenoic acid (EPA), impacts anemia in a specific mouse model of sickle cell disease (SCD). SCD often leads to severe anemia and other serious health issues. Our investigation revealed that SC411 increased the levels of both docosahexaenoic acid (DHA) and EPA in the blood, which are essential fatty acids known to have beneficial effects on health.
Furthermore, we observed that SC411 helped decrease harmful arachidonic acid levels and reduced the sickling of red blood cells, thereby potentially alleviating some of the pain and complications associated with the disease. The treatment not only improved cerebral blood flow but also seemed to enhance cognitive functions, like memory, in the mice.
Overall, the results highlighted that treatment with SC411 could significantly enhance survival rates in mice with SCD through improved cellular and functional outcomes, paving the way for new therapeutic strategies to handle ischemic injuries related to this debilitating condition.
Furthermore, we observed that SC411 helped decrease harmful arachidonic acid levels and reduced the sickling of red blood cells, thereby potentially alleviating some of the pain and complications associated with the disease. The treatment not only improved cerebral blood flow but also seemed to enhance cognitive functions, like memory, in the mice.
Overall, the results highlighted that treatment with SC411 could significantly enhance survival rates in mice with SCD through improved cellular and functional outcomes, paving the way for new therapeutic strategies to handle ischemic injuries related to this debilitating condition.
Read More
Most Useful Reviews
8.8
Improved anaemia management
I began using Now supplements for my overall health. As a CKD sufferer, I must be cautious with the supplements I take. I can confidently say these have significantly improved my condition, especially concerning the anaemia associated with CKD. The pills are easy to swallow, offer great value, and have no discernible taste.
Read More
9.5
Normalised anaemia levels
I take one tablet each morning and evening. After six months of use, my anaemia has returned to normal. I'm combining this oil with multivitamins as recommended, and it seems to be working well.
Read More
9.5
Improved health readings
I have no complaints about this product. After taking Omega-3, my slight anaemia post-COVID improved significantly, with my haemoglobin levels approaching normal. I appreciate this brand's products and continue to take two tablets after breakfast.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 26 Researches
7.5
9
EPA may prevent anemia risk
Prophylaxis for ribavirin-related anemia using eicosapentaenoic acid in chronic hepatitis C patients.
Relevant study on EPA and anemia
We examined the effectiveness of eicosapentaenoic acid (EPA) in preventing anemia caused by ribavirin during hepatitis C treatment. This study involved twelve chronic hepatitis C patients, aged between 3 and 21 years, who were divided into two groups: one receiving EPA and the other acting as a control. Blood samples were collected at various intervals to monitor changes in hemoglobin levels and ribavirin concentrations throughout the treatment period.
Our findings revealed that those who received EPA experienced significantly less reduction in hemoglobin levels compared to the control group. In fact, by weeks eight and sixteen, the protective effects against anemia were clear and statistically significant. While we did not observe any notable differences in ribavirin drug levels between the two groups, one patient in the control group had to lower their ribavirin dosage due to anemia.
Overall, our research underscores the potential of EPA supplementation as a preventative measure against ribavirin-related anemia in young patients undergoing treatment for hepatitis C. This offers a promising strategy to improve treatment adherence and outcomes for this vulnerable population.
Our findings revealed that those who received EPA experienced significantly less reduction in hemoglobin levels compared to the control group. In fact, by weeks eight and sixteen, the protective effects against anemia were clear and statistically significant. While we did not observe any notable differences in ribavirin drug levels between the two groups, one patient in the control group had to lower their ribavirin dosage due to anemia.
Overall, our research underscores the potential of EPA supplementation as a preventative measure against ribavirin-related anemia in young patients undergoing treatment for hepatitis C. This offers a promising strategy to improve treatment adherence and outcomes for this vulnerable population.
Read More
9
Docosahexaenoic acid aids β-thalassemia
Comparative effectiveness of adding omega-3 and Manuka honey combination to conventional therapy in preventing and treating oxidative stress in pediatric β-thalassemia major - a randomized clinical trial.
Score reflects mixed effects.
We conducted a study to explore the effectiveness of docosahexaenoic acid (DHA) when combined with Manuka honey, aimed at improving health outcomes for children suffering from β-thalassemia major. This condition is known for causing significant oxidative stress and iron overload, which can lead to various complications.
In a well-structured, randomized clinical trial involving 165 pediatric patients, we had them placed into three distinct groups. One group received omega-3 fish oil containing DHA along with Manuka honey, while another received only Manuka honey, and the last group continued with conventional therapies like deferasirox and blood transfusions.
Our findings suggested that the combination of omega-3 and Manuka honey was significantly more effective than either Manuka honey on its own or the conventional treatments alone in managing oxidative stress levels in these young patients.
However, it’s important to note that while we observed positive results in combating oxidative stress, we cannot definitively isolate DHA's effects on anemia alone, as it was always paired with the honey and other treatments.
In a well-structured, randomized clinical trial involving 165 pediatric patients, we had them placed into three distinct groups. One group received omega-3 fish oil containing DHA along with Manuka honey, while another received only Manuka honey, and the last group continued with conventional therapies like deferasirox and blood transfusions.
Our findings suggested that the combination of omega-3 and Manuka honey was significantly more effective than either Manuka honey on its own or the conventional treatments alone in managing oxidative stress levels in these young patients.
However, it’s important to note that while we observed positive results in combating oxidative stress, we cannot definitively isolate DHA's effects on anemia alone, as it was always paired with the honey and other treatments.
Read More
9
DHA enhances sickle cell outcomes
SC411 treatment can enhance survival in a mouse model of sickle cell disease.
Study shows mixed fatty acid effects
We explored the potential of docosahexaenoic acid (DHA) as a treatment for anemia in sickle cell disease (SCD). In this study, we utilized a special mouse model that mimics SCD, testing how SC411—a purified form of DHA—affects this condition.
After eight weeks of treatment, we observed that DHA levels, along with eicosapentaenoic acid (EPA), significantly increased in the blood of the SCD mice. Alongside these positive changes, we found that SC411 also reduced levels of arachidonic acid, minimizing the sickling of red blood cells, which is a major issue in SCD.
Notably, mice that received SC411 showcased improvements in blood flow to the brain, a decrease in neuroinflammation, and even an enhancement in working memory. These findings ultimately led to improved survival rates among the treated mice, suggesting that DHA can offer a promising therapeutic avenue for individuals suffering from SCD and its related anemia.
After eight weeks of treatment, we observed that DHA levels, along with eicosapentaenoic acid (EPA), significantly increased in the blood of the SCD mice. Alongside these positive changes, we found that SC411 also reduced levels of arachidonic acid, minimizing the sickling of red blood cells, which is a major issue in SCD.
Notably, mice that received SC411 showcased improvements in blood flow to the brain, a decrease in neuroinflammation, and even an enhancement in working memory. These findings ultimately led to improved survival rates among the treated mice, suggesting that DHA can offer a promising therapeutic avenue for individuals suffering from SCD and its related anemia.
Read More
9
Maresin 1 helps treat anemia
Maresin 1 ameliorates iron-deficient anemia in IL-10(-/-) mice with spontaneous colitis by the inhibition of hepcidin expression though the IL-6/STAT3 pathway.
Study directly investigates MaR1 effects
We focused on how Maresin 1, a compound derived from docosahexaenoic acid, might help improve iron-deficient anemia in mice with chronic colitis. Our research involved IL-10 knockout mice, which are known to develop spontaneous colitis and associated anemia.
Over two weeks, we treated these mice with MaR1, observing several important changes. We found that MaR1 significantly reduced inflammation in the colon and was associated with a boost in hemoglobin levels, increased serum iron, and improved transferrin saturation.
Additionally, we noted that the levels of hepcidin, a protein that regulates iron metabolism and is often elevated during inflammation, decreased after treatment. This suggests that MaR1 helps combat anemia by influencing this protein's expression through the IL-6/STAT3 pathway.
Overall, we uncovered promising evidence that MaR1 has the potential to alleviate anemia connected to inflammatory processes, making it a noteworthy area for further exploration in treating patients with similar conditions.
Over two weeks, we treated these mice with MaR1, observing several important changes. We found that MaR1 significantly reduced inflammation in the colon and was associated with a boost in hemoglobin levels, increased serum iron, and improved transferrin saturation.
Additionally, we noted that the levels of hepcidin, a protein that regulates iron metabolism and is often elevated during inflammation, decreased after treatment. This suggests that MaR1 helps combat anemia by influencing this protein's expression through the IL-6/STAT3 pathway.
Overall, we uncovered promising evidence that MaR1 has the potential to alleviate anemia connected to inflammatory processes, making it a noteworthy area for further exploration in treating patients with similar conditions.
Read More
9
DHA improves RBC flexibility in anemia
Dietary supplementation with docosahexanoic acid (DHA) increases red blood cell membrane flexibility in mice with sickle cell disease.
Moderate relevance to anemia study
We explored the impact of docosahexaenoic acid (DHA), a type of omega-3 fatty acid, on red blood cells (RBCs) in mice with sickle cell disease (SCD). The research focused on whether DHA could improve RBC stiffness and deformability, which are crucial factors in anemia related to SCD.
To conduct our study, sickle cell mice were given diets with either 3% DHA or a control diet rich in total fat for eight weeks. We used advanced methods to assess the stiffness and flexibility of the RBCs, along with analyzing blood smears for the presence of irreversibly sickled RBCs.
Our findings were quite striking. We observed that the mice consuming the DHA diet showed significantly improved RBC flexibility and a reduction in the number of irreversibly sickled cells by approximately 40%, compared to those on the control diet. This suggests that DHA supplementation may have therapeutic potential in enhancing RBC function and potentially alleviating some symptoms of anemia in sickle cell disease.
Overall, our study underscores the role of dietary omega-3 fatty acids like DHA in managing conditions associated with rigid and sickled red blood cells. While more research is needed to fully understand the implications, these results offer a promising perspective on dietary interventions for sickle cell disease.
To conduct our study, sickle cell mice were given diets with either 3% DHA or a control diet rich in total fat for eight weeks. We used advanced methods to assess the stiffness and flexibility of the RBCs, along with analyzing blood smears for the presence of irreversibly sickled RBCs.
Our findings were quite striking. We observed that the mice consuming the DHA diet showed significantly improved RBC flexibility and a reduction in the number of irreversibly sickled cells by approximately 40%, compared to those on the control diet. This suggests that DHA supplementation may have therapeutic potential in enhancing RBC function and potentially alleviating some symptoms of anemia in sickle cell disease.
Overall, our study underscores the role of dietary omega-3 fatty acids like DHA in managing conditions associated with rigid and sickled red blood cells. While more research is needed to fully understand the implications, these results offer a promising perspective on dietary interventions for sickle cell disease.
Read More
User Reviews
USERS' SCORE
Good
Based on 5 Reviews
8.7
9.5
Normalised anaemia levels
I take one tablet each morning and evening. After six months of use, my anaemia has returned to normal. I'm combining this oil with multivitamins as recommended, and it seems to be working well.
9.5
Improved health readings
I have no complaints about this product. After taking Omega-3, my slight anaemia post-COVID improved significantly, with my haemoglobin levels approaching normal. I appreciate this brand's products and continue to take two tablets after breakfast.
8.8
Improved anaemia management
I began using Now supplements for my overall health. As a CKD sufferer, I must be cautious with the supplements I take. I can confidently say these have significantly improved my condition, especially concerning the anaemia associated with CKD. The pills are easy to swallow, offer great value, and have no discernible taste.
Read More
8.8
Reduced hair fallout
Having undergone hair straightening eight years ago, my hair became brittle and began to fall out excessively, particularly due to my anaemia and iron deficiency. After two months of taking Omega-3 and Gold C, I was pleasantly surprised by the significant reduction in hair fallout. Although I haven't noticed improvements in my skin, my hair has begun to recover.
Read More
8.8
Decreased anaemia symptoms
After taking this supplement for two months, I have noticed a reduction in signs of anaemia. I plan to continue using it in the future.
